August 16, 2021 7:47am
Let’s ease into the week after many record closes while enduring a foreign military disaster in Afghanistan
The Biostage (BSTG) Chronicles: earnings’ release and 8-K & 10-Q filed… so WHAT is the value proposition WHEN they’re BROKE?
Pre-open indications: 1 Maintain SELL
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
There is no breadline for fact and numbers-based share pricing intelligence!
Dow futures are DOWN -0.24% (-86 points), S&P futures are DOWN -0.24% (-11 point) and NASDAQ futures are DOWN -0.24% (-36 points)
Futures contracts tied to the major U.S. stock indexes are down and slipping on Monday
European stocks were lower
Asia-Pacific stocks slipped after the release of Chinese economic data for July. South Korea’s markets were closed on Monday for a holiday; Japan, Australia also fell.
- Retail sales in China rose 8.5% in July as compared with a year ago, according to official data released Monday. That was far lower than the 11.5% rise forecasted while industrial production grew 6.4% in July, also falling short of expectations for a 7.8% year-on-year increase for the month. < Reuters>
Data Docket: Upcoming economic data includes an update on retail sales on Tuesday, as well as housing starts and the release of the Federal Reserve’s latest meeting minutes on Wednesday.
Henry’omics:
The Dow gained +0.8%, the S&P 500 rose +0.7% Nasdaq underperformed just under 0.1% with low trading volumes.
Markets are closely watching from the distance the debacle and geopolitical implications of the abrupt collapse of the Afghanistan government.
Friday’s evening’s recap: “RegMed Investors’ (RMi) closing bell: sector wavers with minimal percentage movement, low volume and lack of breath” … https://www.regmedinvestors.com/articles/12049
- The Nasdaq closed barely UP +6.64 points (+0.04%);
- The IBB closed up +0.16% and XBI closed down -1.71%;
- Sector volume was LOW with 1 of the 6-upside having higher than the 3-month average volume with very LOW volume of 5 of 24-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was down -0.14 points or -0.90% at 15.45;
- Friday’s percentage (%) of the 6-upside were +0.03% (RARE) to +1.31% (FIXX) while the 24-downside -0.32% (PSTI) to -6.37% (CRSP);
Q3/21:
- August: 5 positive and 5 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Q2/21:
- June: 15 positive and 8 negative closes
- May: 8 positive, 12 negative closes and 1 holiday
- April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with and without being “pumped/promoted”?
Biostage (BSTG) closed flat again on Friday with 10 shares traded after Thursday and Wednesday with 50 shares traded following Tuesday with 4 shares traded and last Monday’s down -$0.05 with 1060 shares traded.
The Bottom-Line Question: WHAT is the end game or play-book for this company, it has NOT done ANYTHING to monetize their asset of an approved IND foe a year and a half with NO clinical trial initiative … so WHAT is the value proposition WHEN they’re BROKE?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Pre-open Indications: No prognostications today in this fragile market and the beginning of vacation.
The BOTTOM LINE: Three (3) negative closes out of five (5) sessions last week …
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC), Mesoblast (MESO), Pluristem (PSTI) and Solid Biosciences (SLDB), Pluristem (PSTI), ReNeuron (RENE.L)
Remember: Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out.
Risk is no doubt increasing as we head into the troublesome August and September months
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
